VolparaEnterprise helps clinics to improve their standard of care, detect cancers earlier and meet the FDA’s EQUIP regulations. The cloud-based platform has a clearly defined return on investment in a market estimated to be worth A$1 billion globally.
With breast density notification laws now in 32 US states, this is driving significant interest in Volpara’s solutions as demonstrated at GE’s recent US roadshow.
